Cancer Treatment Reviews
Volume 25, Issue 4 , Pages 229-235 , August 1999

Fenretinide and its relation to cancer

References 

    REFERENCES
  1. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Federation Proceedings. 1976;35:1332–1338
  2. Chan LN, Zhang S, Shao J, Waikel R, Thompson EA, Chan TS. N-(4-hydroxyphenyl) retinamide induces apoptosis in T lymphoma and T lymphoblastoid leukemia cells. Leukemia and Lymphoma. 1997;25:271–280
  3. Wang TT, Phang JM. Effect of N-(4-hydroxyphenyl)retinamide on apoptosis in human breast cancer cells. Cancer Letters. 1996;107:65–71
  4. Kalemkerian GP, Slusher R, Ramalingam S, Gadgeel S, Mabry M. Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines. Journal of the National Cancer Institute. 1995;87:1674–1680
  5. Zou CP, Kurie JM, Lotan D, Zou CC, Hong WK, Lotan R. Higher potency of N-(4-hydroxyphenyl)retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. Clinical Cancer Research. 1998;4:1345–1355
  6. Igawa M, Tanabe T, Chodak GW, Rukstalis DB. N-(4-hydroxyphenyl) retinamide induces cell cycle specific growth inhibition in PC3 cells. Prostate. 1994;24:299–305
  7. Eicher SA, Lotan R. Differential effects of retinoic acid and N-(4-hydroxyphenyl) retinamide on head and neck squamous cell carcinoma cells. Laryngoscope. 1996;106:1471–1475
  8. Scher RL, Saito W, Dodge RK, Richtsmeier WJ, Fine RL. Fenretinide-induced apoptosis of human head and neck squamous carcinoma cell lines. Otolaryngology Head and Neck Surgery. 1998;118:464–471
  9. Montaldo PG, Pagnan G, Pastorino F. N-(4-hydroxyphenyl) retinamide is cytotoxic to melanoma cells in vitro through induction of programmed cell death. International Journal of Cancer. 1999;81:262–267
  10. Zheng Y, Kramer PM, Lubet RA, Steele VE, Kelloff GJ, Pereira MA. Effect of retinoids on AOM-induced colon cancer in rats: modulation of cell proliferation, apoptosis and aberrant crypt foci. Carcinogenesis. 1999;20:255–260
  11. Zheng Y, Kramer PM, Olson G, Lubet RA, Steele VE, Kelloff GJ, et al. Prevention by retinoids of azoxymethane-induced tumours and aberrant crypt foci and their modulation of cell proliferation in the colon of rats. Carcinogenesis. 1997;18:2119–2125
  12. Silverman J, Katayama S, Zelenakas K. Effects of retinoids on the induction of colon cancer in F344 rats by N-methyl-N-nitrosourea or by 1,2-dimethylhydrazine. Carcinogenesis. 1981;2:1167–1172
  13. Dowlatshahi K, Mehta RG, Thomas CF, Dinger NM and Moon RC. Therapeutic effect of N-(4-hydroxyphenyl)retinamide on N-methyl-N-nitrosourea-induced rat mammary cancer. Cancer Letters. 1989;47:187–192
  14. Moon RC, Kelloff GJ, Detrisac CJ, Steele VE, Thomas CF, Sigman CC. Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen. Anticancer Research. 1992;12:1147–1153
  15. Becci PJ, Thompson JH, Sporn MB, Moor RC. Retinoid inhibition of highly invasive urinary bladder carcinomas induced in mice by N-butyl-N-(4-hydoxybutyl)nitrosamine (OH-BBN). Proc Am Assoc Cancer Res. 1980;21:88
  16. Tamura K, Nakae D, Horiguchi K. Inhibition by N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid of exogenous and endogenous development of putative preneoplastic, glutathione S-transferase placental form- positive lesions in the livers of rats. Carcinogenesis. 1997;18:2133–2141
  17. Birt DF, Sayed S, Davies MH, Pour P. Sex differences in the effects of retinoids on carcinogenesis by N-nitrosobis(2-oxopropyl)amine in Syrian hamsters. Cancer Letters. 1981;14:13–21
  18. McCormick DL, Moon RC. Antipromotional activity of dietary N-(4-hydroxyphenyl)retinamide in two-stage skin tumorigenesis in CD-1 and SENCAR mice. Cancer Letters. 1986;31:133–138
  19. Ohshima M, Ward JM, Wenk ML. Preventive and enhancing effects of retinoids on the development of naturally occurring tumors of skin, prostate gland, and endocrine pancreas in aged male ACI/segHapBR rats. Journal of the National Cancer Institute. 1985;74:517–524
  20. Formelli F, Cleris L. Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Research. 1993;53:5374–5376
  21. Conaway CC, Jiao D, Kelloff GJ, Steele VE, Rivenson A, Chung FL. Chemopreventive potential of fumaric acid, N-acetylcysteine, N-β4-hydroxyphenyl) retinamide and (-carotene for tobacco-nitrosamine-induced lung tumors in A/J mice. Cancer Letters. 1998;124:85–93
  22. McCormick DL, Rao KV, Dooley L. Influence of N-methyl-N-nitrosourea, testosterone, and N-(4-hydroxyphenyl)-all-trans-retinamide on prostate cancer induction in Wistar-Unilever rats. Cancer Research. 1998;58:3282–3288
  23. Pollard M, Luckert PH, Sporn MB. Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide. Cancer Research. 1991;51:3610–3611
  24. Costa A, De Palo G, Decensi A. Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide [Review]. Annals of the New York Academy of Sciences. 1995;768:148–162
  25. Naik HR, Kalemkerian G, Pienta KJ. 4-Hydroxyphenylretinamide in the chemoprevention of cancer [Review]. Advances in Pharmacology. 1995;33:315–347
  26. Moon RC, Thompson HJ, Becci PJ. N-(4-hydoxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Research. 1979;39:1339–1346
  27. Swanson BN, Zaharevitz DW, Sporn MB. Pharmacokinetics of N-4-hydroxyphenyl-all-trans-retinamide in rats. Drug Metabolism and Disposition. 1980;8:168–172
  28. Hultin TA, May CM, Moon RC. N-(4-hydroxyphenyl)-all-trans-retinamide pharmacokinetics in female rats and mice. Drug Metabolism and Disposition. 1986;14:714–717
  29. Costa A, Malone W, Perloff M. Tolerability of the synthetic retinoid fenretinide (HPR). European Journal of Cancer and Clinical Oncology. 1989;25:805–808
  30. Swanson BN, Newton DL, Roller PP, Sporn MB. Biotransformation and biological activity of N-(4-hydroxyphenyl)retinamide derivatives in rodents. Journal of Pharmacology and Experimental Therapeutics. 1981;219:632–637
  31. Hultin TA, Filla MS, McCormick DL. Distribution and metabolism of the retinoid, N-(4-methoxyphenyl)-all-trans-retinamide, the major metabolite of N-(4-hydroxyphenyl)- all-trans-retinamide, in female mice. Drug Metabolism and Disposition. 1990;18:175–179
  32. Kazmi SM, Plante RK, Visconti V, Lau CY. Comparison of N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines. Cancer Research. 1996;56:1056–1062
  33. Jinno H, Steiner MG, Mehta RG, Osborne MP, Telang NT. Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl)retinamide. Carcinogenesis. 1999;20:229–236
  34. Mehta RR, Hawthorne ME, Graves JM, Mehta RG. Metabolism of N-[4-hydroxyphenyl]retinamide (4-HPR) to N-[4-methoxyphenyl]retinamide (4-MPR) may serve as a biomarker for its efficacy against human breast cancer and melanoma cells. European Journal of Cancer. 1998;34:902–907
  35. Torrisi R, Pensa F, Fontana V, Costa A, Decensi A. The metabolite N-4-methoxyphenylretinamide is a major determinant of fenretinide induced decline of plasma insulin-like growth factor-1 [letter]. European Journal of Cancer. 1995;31A:420–421
  36. Decensi A, Formelli F, Torrisi R, Costa A. Breast cancer chemoprevention: studies with 4-HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate endpoints. Journal of Cellular Biochemistry Supplement. 1993;17G:226–233
  37. Schaffer EM, Ritter SJ, Smith JE. N-(4-hydroxyphenyl)retinamide (fenretinide) induces retinol-binding protein secretion from liver and accumulation in the kidneys in rats. Journal of Nutrition. 1993;123:1497–1503
  38. Smith JE, Lawless DC, Green MH, Moon RC. Secretion of vitamin A and retinol-binding protein into plasma is depressed in rats by N-(4-hydroxyphenyl)retinamide (fenretinide). Journal of Nutrition. 1992;122:1999–2009
  39. Ritter SJ and Smith JE. Retinol-binding protein secretion from the liver of N-(4-hydroxyphenyl) retinamide-treated rats. Biochimica et Biophysica Acta. 1996;1290:157–164
  40. Holven KB, Natarajan V, Gundersen TE, Moskaug JO, Norum KR, Blomhoff R. Secretion of N-(4-hydroxyphenyl) retinamide-retinol-binding protein from liver parenchymal cells: evidence for reduced affinity of the complex for transthyretin. International Journal of Cancer. 1997;71:654–659
  41. Formelli F, Clerici M, Campa T. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. Journal of Clinical Oncology. 1993;11:2036–2042
  42. Formelli F, Carsana R, Costa A. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients. Cancer Research. 1989;49:6149–6152
  43. Moglia D, Formelli F, Baliva G. Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses. Cancer Letters. 1996;110:87–91
  44. Taimi M, Breitman TR. N-4-hydroxyphenylretinamide enhances retinoic acid-induced differentiation and retinoylation of proteins in the human acute promyelocytic leukemia cell line, NB4, by a mechanism that may involve inhibition of retinoic acid catabolism. Biochemical and Biophysical Research Communications. 1997;232:432–436
  45. Fanjul AN, Delia D, Pierotti MA, Rideout D, Qiu J, Pfahl M. 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. Journal of Biological Chemistry. 1996;271:22441–22446
  46. Liu G, Wu M, Levi G, Ferrari N. Inhibition of cancer cell growth by all-trans retinoic acid and its analog N-(4-hydroxyphenyl) retinamide: a possible mechanism of action via regulation of retinoid receptors expression. International Journal of Cancer. 1998;78:248–254
  47. Sheikh MS, Shao ZM, Li XS. N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis. 1995;16:2477–2486
  48. Delia D, Aiello A, Lombardi L. N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Research. 1993;53:6036–6041
  49. Brigati C, Ferrari N, Megna M. A retinoic acid resistant HL-60 cell clone sensitive to N-(4-hydroxyphenyl) retinamide-mediated clonal growth inhibition. Leukemia and Lymphoma. 1995;17:175–180
  50. Ponzoni M, Bocca P, Chiesa V. Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Research. 1995;55:853–861
  51. Dipietrantonio A, Hsieh TC, Wu JM. Differential effects of retinoic acid (RA) and N-(4-hydroxyphenyl) retinamide (4-HPR) on cell growth, induction of differentiation, and changes in p34cdc2, Bcl-2, and actin expression in the human promyelocytic HL-60 leukemic cells. Biochemical and Biophysical Research Communications. 1996;224:837–842
  52. Oridate N, Suzuki S, Higuchi M, Mitchell MF, Hong WK, Lotan R. Involvement of reactive oxygen species in N-(4-hydroxyphenyl) retinamide-induced apoptosis in cervical carcinoma cells. Journal of the National Cancer Institute. 1997;89:1191–1198
  53. Delia D, Aiello A, Meroni L, Nicolini M, Reed JC, Pierotti MA. Role of antioxidants and intracellular free radicals in retinamide-induced cell death. Carcinogenesis. 1997;18:943–948
  54. Rozzo C, Chiesa V, Caridi G, Pagnan G, Ponzoni M. Induction of apoptosis in human neuroblastoma cells by abrogation of integrin-mediated cell adhesion. International Journal of Cancer. 1997;70:688–698
  55. Pellegrini R, Mariotti A, Tagliabue E. et al. Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide. Cell Growth and Differentiation. 1995;6:863–869
  56. Roberson KM, Penland SN, Padilla GM. Fenretinide: induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells. Cell Growth and Differentiation. 1997;8:101–111
  57. Muller A, Nakagawa H, Rustgi AK. Retinoic acid and N-(4-hydroxyphenyl) retinamide suppress growth of esophageal squamous carcinoma cell lines. Cancer Letters. 1997;113:95–101
  58. Oridate N, Lotan D, Mitchell MF, Hong WK, Lotan R. Inhibition of proliferation and induction of apoptosis in cervical carcinoma cells by retinoids: implications for chemoprevention. Journal of Cellular Biochemistry -Supplement. 1995;23:80–86
  59. Delia D, Aiello A, Formelli F. Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated Bcl-2. Blood. 1995;85:359–367
  60. Hsieh TC, Ng C, Wu JM. The synthetic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR) exerts antiproliferative and apoptosis-inducing effects in the androgen-independent human prostatic JCA-1 cells. Biochemistry and Molecular Biology International. 1995;37:499–506
  61. Supino R, Crosti M, Clerici M. Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. International Journal of Cancer. 1996;65:491–497
  62. Webb TE, Abou-Issa H, Stromberg PC, Curley RC, Nguyen MH. Mechanism of growth inhibition of mammary carcinomas by glucarate and the glucarate: retinoid combination. Anticancer Research. 1993;13:2095–2099
  63. Roberson KM, Penland SN, Padilla GM. Fenretinide: induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells. Cell Growth and Differentiation. 1997;8:101–111
  64. Coradini D, Biffi A, Pellizzaro C, Pirronello E, Di Fronzo G. Combined effect of tamoxifen or interferon-beta and 4-hydroxyphenylretinamide on the growth of breast cancer cell lines. Tumour Biology. 1997;18:22–29
  65. Moon RC, Kelloff GJ, Detrisac CJ, Steele VE, Thomas CF, Sigman CC. Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and and tamoxifen. Anticancer Research. 1992;12:1147–1153
  66. Cobleigh MA. Breast cancer and fenretinide, an analogue of vitamin A. [Review]. Leukemia. 1994;8:S59–63
  67. Ziv Y, Gupta MK, Milsom JW, Vladisavljevic A, Brand M, Fazio VW. The effect of tamoxifen and fenretinimide on human colorectal cancer cell lines in vitro. Anticancer Research. 1994;14:2005–2009
  68. Zou C, Wang L, Liebert M, Grossman HB, Lotan R, Wei Q. Combined effect of chemopreventive agent N-(4-hydroxyphenyl) retinamide (4-HPR) and gamma-radiation on bladder cancer cell lines. International Journal of Oncology. 1998;13:1037–1041
  69. Kelloff, GJ, Chemoprevention Branch and Agent Development Committee, Division of Cancer Prevention and Control, National CancerInstitute, Clinical development plan: N-(4-hydroxyphenyl) retinamide (4-HPR), 1994, 20, 176, 196
  70. Costa A, Malone W, Perloff M. Tolerability of the synthetic retinoid Fenretinide (HPR). European Journal of Cancer and Clinical Oncology. 1989;25:805–808
  71. Cobleigh MA, Dowlatshahi K, Deutsch TA. Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. Journal of Clinical Oncology. 1993;11:447–474
  72. Modiano MR, Dalton WS, Lippman SM, Joffe L, Booth AR, Meyskens FL. Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma. Investigational New Drugs. 1990;8:317–319
  73. Pienta KJ, Esper PS, Zwas F, Krzeminski R, Flaherty LE. Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate. American Journal of Clinical Oncology. 1997;20:36–39
  74. Costa A, Formelli F, Chiesa F, Decensi A, De Palo G, Veronesi U. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. [Review]. Cancer Research. 1994;54:2032s–2037s
  75. Chiesa F, Tradati N, Marazza M. Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. Journal of Cellular Biochemistry. 1993;17F:255–261
  76. Garewal HS, List A, Meyskens F, Buzaid A, Greenberg B, Katakkar S. Phase II trial of fenretinide [N-(4-hydroxyphenyl) retinamide] in myelodysplasia: possible retinoid-induced disease acceleration. Leukemia Research. 1989;13:339–343
  77. De Palo G, Veronesi U, Marubini E. Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakia. [Review]. Journal of Cellular Biochemistry-Supplement. 1995;22:11–17

PII: S0305-7372(99)90127-5

doi: 10.1053/ctrv.1999.0127

Cancer Treatment Reviews
Volume 25, Issue 4 , Pages 229-235 , August 1999

Article Tools